Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30340428 | 0.90 | AGTR2 (0.40) | UCHL1AGTR2HSD17B10NR1H2ABCB1 | |
| SCHEMBL30340394 | 0.90 | AGTR2 (0.40) | UCHL1AGTR2HSD17B10NR1H2ABCB1 | |
| SCHEMBL31289157 | 0.90 | P2RX3 (0.37) | UCHL1AGTR2HSD17B10JAK2JAK1 | |
| SCHEMBL30556148 | 0.90 | P2RX3 (0.37) | UCHL1AGTR2HSD17B10JAK2JAK1 | |
| SCHEMBL12800440 | 0.88 | AGTR2 (0.39) | UCHL1AGTR2HSD17B10NR1H2ABCB1 | |
| SCHEMBL6848108 | 0.85 | MCL1 (0.38) | UCHL1AGTR2HSD17B10NR1H2SMN1; SMN2 | |
| SCHEMBL20446593 | 0.85 | MCL1 (0.38) | UCHL1AGTR2HSD17B10NR1H2SMN1; SMN2 | |
| SCHEMBL6848111 | 0.85 | MCL1 (0.38) | UCHL1AGTR2HSD17B10NR1H2SMN1; SMN2 | |
| SCHEMBL6848260 | 0.85 | MCL1 (0.38) | UCHL1AGTR2HSD17B10NR1H2SMN1; SMN2 | |
| SCHEMBL6848258 | 0.85 | MCL1 (0.38) | UCHL1AGTR2HSD17B10NR1H2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205167-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SAIL BIOMEDICINES, INC. | 2025-06-26 | — | — | US | disclosed |
| EP-4499607-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | Sail Biomedicines, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119072464-A | Novel ionizable lipids and lipid nanoparticles and methods of use thereof | 赛欧生物医药股份有限公司 | 2024-12-03 | — | — | CN | disclosed |
| WO-2023183616-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SENDA BIOSCIENCES, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205167-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | PHOSPHO1, SGMS2, SGMS1 | UCHL1 4474/4885AGTR2 3736/4885HSD17B10 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.